Department of Radiology, Stanford University School of Medicine, 300 Pasteur Dr, Rm H-1307, Stanford, CA 94305.
Department of Urology, Stanford University School of Medicine, Palo Alto, CA.
AJR Am J Roentgenol. 2022 Aug;219(2):244-253. doi: 10.2214/AJR.22.27400. Epub 2022 Mar 16.
Active surveillance is increasingly used as first-line management for localized renal masses. Triggers for intervention primarily reflect growth kinetics, which have been poorly investigated for cystic masses defined by the Bosniak classification version 2019 (v2019). The purpose of this study was to determine growth kinetics and incidence rates of progression of class III and IV cystic renal masses, as defined by the Bosniak classification v2019. This retrospective study included 105 patients (68 men, 37 women; median age, 67 years) with 112 Bosniak v2019 class III or IV cystic renal masses on baseline renal mass protocol CT or MRI examinations performed from January 2005 to September 2021. Mass dimensions were measured. Progression was defined as any of the following: linear growth rate (LGR) of 5 mm/y or greater (representing the clinical guideline threshold for intervention), volume doubling time less than 1 year, T category increase, or N1 or M1 disease. Class III and IV masses were compared. Time to progression was estimated using Kaplan-Meier curve analysis. At baseline, 58 masses were class III and 54 were class IV. Median follow-up was 403 days. Median LGR for class III masses was 0.0 mm/y (interquartile range [IQR], -1.3 to 1.8 mm/y) and for class IV masses was 2.3 mm/y (IQR, 0.0-5.7 mm/y) ( < .001). LGR was at least 5 mm/y in four (7%) class III masses and 15 (28%) class IV masses ( = .005). Two patients, both with class IV masses, developed distant metastases. Incidence rate of progression for class III masses was 11.0 (95% CI, 4.5-22.8) and for class IV masses 73.6 (95% CI, 47.8-108.7) per 100,000 person-days of follow-up. Median time to progression was undefined for class III masses given the small number of progression events and 710 days for class IV masses. Hazard ratio of progression for class IV relative to class III masses was 5.1 (95% CI, 2.5-10.8; < .001). During active surveillance of cystic masses evaluated using the Bosniak classification v2019, class IV masses grew faster and were more likely to progress than class III masses. In comparison with current active surveillance guidelines that treat class III and IV masses similarly, future iterations may incorporate relatively more intensive surveillance for class IV masses.
主动监测越来越多地被用作局灶性肾肿瘤的一线治疗方法。干预的触发因素主要反映了生长动力学,而对于 2019 年版 Bosniak 分类(v2019)定义的囊性肿块,生长动力学的研究甚少。本研究的目的是确定 2019 年版 Bosniak 分类的 III 类和 IV 类囊性肾肿瘤的生长动力学和进展发生率。这项回顾性研究纳入了 105 名患者(68 名男性,37 名女性;中位年龄 67 岁),他们在 2005 年 1 月至 2021 年 9 月期间接受了肾脏肿块方案 CT 或 MRI 检查,基线时存在 112 个 Bosniak v2019 级 III 或 IV 囊性肾肿瘤。测量了肿块的尺寸。进展定义为以下任何一种情况:线性生长率(LGR)≥5mm/y(代表干预的临床指南阈值)、体积倍增时间<1 年、T 分期增加或 N1 或 M1 疾病。比较了 III 类和 IV 类肿块。使用 Kaplan-Meier 曲线分析估计进展时间。基线时,58 个肿块为 III 级,54 个为 IV 级。中位随访时间为 403 天。III 级肿块的中位 LGR 为 0.0mm/y(四分位距 [IQR],-1.3 至 1.8mm/y),IV 级肿块为 2.3mm/y(IQR,0.0 至 5.7mm/y)(<0.001)。四个(7%)III 级肿块和 15 个(28%)IV 级肿块的 LGR 至少为 5mm/y(=0.005)。两名患者均为 IV 级肿块,发生远处转移。III 级肿块的进展发生率为 11.0(95%CI,4.5-22.8),IV 级肿块为 73.6(95%CI,47.8-108.7)/100000 人-年。由于进展事件数量较少,III 级肿块的中位进展时间未定义,IV 级肿块的中位进展时间为 710 天。IV 级与 III 级肿块相比,进展的风险比为 5.1(95%CI,2.5-10.8;<0.001)。在使用 Bosniak 分类 v2019 评估的囊性肿块的主动监测中,IV 级肿块的生长速度更快,比 III 级肿块更容易进展。与目前类似治疗 III 级和 IV 级肿块的主动监测指南相比,未来的迭代可能会对 IV 级肿块进行相对更密集的监测。